These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Screening of the pathogen box for the identification of anti-Acanthamoeba agents.
    Author: Sifaoui I, Reyes-Batlle M, López-Arencibia A, Chiboub O, Bethencourt-Estrella CJ, San Nicolás-Hernández D, Rodríguez Expósito RL, Rizo-Liendo A, Piñero JE, Lorenzo-Morales J.
    Journal: Exp Parasitol; 2019 Jun; 201():90-92. PubMed ID: 31059693.
    Abstract:
    Acanthamoeba are free living amoeba that have been isolated from different environments like soil, water, air dust. Moreover, they are also able to act as opportunist pathogens, mainly causing a fatal encephalitis and also keratitis in both human and animals. This study was aimed to evaluate the activity of the Medicines for Malaria Venture (MMV) compounds against the trophozoite stage of Acanthamoeba castellanii Neff. Sixteen compounds showed ≥90% inhibition of parasite growth in the initial screen (10 μM). Those set were further evaluated to determine the inhibitor concentration that inhibit the 50% of the initial population and cytotoxicity against murine macrophages. Among the compounds included in the pathogen box, pentamidine and posaconazole were the most effective against this parasite with an of IC50 of 0.567 ± 0.04 and 0.630 ± 0.11, respectively.
    [Abstract] [Full Text] [Related] [New Search]